CRYO CELL INTERNATIONAL 3Q FY2026: Revenue $7.82M, 10-Q Summary
CRYO CELL INTERNATIONAL INC reported $7.82M in revenue for 3Q FY2026, flat compared to the prior year. Growth in recurring storage fees was offset by fewer new specimen enrollments. The company expanded operational capacity with a new cold storage facility but paused certain initiatives due to a license dispute. Total revenue year-to-date is roughly flat at $23.3M.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public disclosure of flat sales and operational delays, offering new data for traders.
Market read
Micro‑cap earnings with no growth; limited immediate trading relevance.
What to watch
Potential upside from third‑party biorepository services at the new Durham facility.
Background
Cryo‑Cell International filed its Q3 FY2026 10‑Q, reporting flat revenue and a pause on several initiatives due to a licensing dispute.
Ticker impact
Q3 FY2026 revenue of $7.82M flat YoY and paused initiatives signal limited growth.
likely pressure as investors price in stagnant sales and halted projects
Micro‑cap earnings with no growth and a disclosed license dispute indicate limited upside.
Market effects
Minimal impact on broader biotech storage sector; peers may see similar scrutiny on licensing disputes.
Limited to U.S. micro‑cap market; no broader regional effect.
Negligible global relevance.
Counterpoint
If the license dispute resolves quickly, the new facility could drive future revenue growth.
Key entities
- companyCryo Cell International Inc.
Micro‑cap biotech storage firm reporting Q3 results.
